Please login to the form below
Healthcare Glossary
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Cost-effectiveness threshold (health economics)
The ceiling incremental cost-effectiveness ratio (ICER) beyond which interventions are no longer considered cost effective, reflecting the maximum value decision makers attach to health benefits. This may be stated in terms of cost per quality adjusted life year (QALY) gained.
See also:
Decision making unit (DMU)
Cost–benefit analysis
Cost-effective (healthcare economics)
Cost-effectiveness league table (healthcare economics)
Cost-minimisation analysis (CMA)
Cost consequences analysis (CCA)
Related terms
Health technology assessment/appraisal (HTA), Balanced Scorecard, Environmental set, PEEST, Global Health Index, Quality-adjusted life year (QALY), NHS Direct, Morbidity, Performance prism, Compliance, ABPI Code of Practice, Key performance indicator (KPI), Primary care, Respondent, Prophylaxis,
Featured jobs
- FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...
-
Excellent Daily Rate
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Account Director - Medical Communications - London / South East
-
Excellent Salary and Benefits on offer
-
Account Director – UK Office
-
Excellent salary and benefits
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
- Account Director, Healthcare Communications
-
Salary TBC
Subscribe to our email news alerts
- GSK hires Merck KGaA exec to lead US pharma business
- Novartis chooses internal replacement for US pharma president role
- AZ, Merck’s Lynparza scores market-expanding clinical success
- Senators attack Novartis over 'unconscionable' handling of Zolgensma data
- Boris Johnson announces fast-track immigration plans for top scientists
- Lilly psoriasis drug beats J&J's Tremfya in head-to-head trial
- Blended Intelligence
- Planning a pharma exhibition stand? You must read this!
- Leaked no-deal Brexit document forecasts widespread shortages
- AbbVie scores FDA approval for arthritis treatment upadacitinib
- Novo Nordisk shareholder revolt reaches Europe
- BMS buoyed by FDA approval of Celgene’s myelofibrosis drug
PMHub
Nobull Communications
Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...
Quick links
Infographics
